Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia Identifies Lead Compound for Bristol-Myers Squibb

Premium

PRINCETON, NJ--Pharmacopeia reached a milestone in its collaboration with Bristol-Myers Squibb on inflammatory and immunological disease targets when it identified a lead compound, the company announced last week. Bristol-Myers made a cash payment to Pharmacopeia for the achievement.

In just four months, "using our large, rationally designed libraries of small molecules and high-throughput screening, we were able to identify a lead compound against a challenging target and receive confirmation of activity from Bristol-Myers," Pharmacopeia President Joseph Mollica said.

Pharmacopeia combines small molecule combinatorial chemistry with high-throughput screening for drug discovery. Using a proprietary tagging technology, Eclips, the company generates large libraries of diverse, easily identifiable small molecules. With high-throughput screening, it tests compounds in a full complement of assays, including enzyme, receptor binding, and cell-based assays.

Filed under

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.